YMAB Other Current Liab vs Total Stockholder Equity Analysis
YMAB Stock | USD 10.01 0.27 2.63% |
Y MAbs financial indicator trend analysis is more than just analyzing Y mAbs Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Y mAbs Therapeutics is a good investment. Please check the relationship between Y MAbs Other Current Liab and its Total Stockholder Equity accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Other Current Liab vs Total Stockholder Equity
Other Current Liab vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Y mAbs Therapeutics Other Current Liab account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Y MAbs' Other Current Liab and Total Stockholder Equity is 0.68. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Y mAbs Therapeutics, assuming nothing else is changed. The correlation between historical values of Y MAbs' Other Current Liab and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Y mAbs Therapeutics are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Other Current Liab i.e., Y MAbs' Other Current Liab and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.68 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Other Current Liab
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Y MAbs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. As of December 12, 2024, Selling General Administrative is expected to decline to about 33.2 M. In addition to that, Tax Provision is expected to decline to about 308.6 K
2023 | 2024 (projected) | Depreciation And Amortization | 735K | 540.3K | Interest Income | 687.7K | 979.4K |
Y MAbs fundamental ratios Correlations
Click cells to compare fundamentals
Y MAbs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Y MAbs fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 216.4M | 132.0M | 212.8M | 141.5M | 127.9M | 150.1M | |
Other Current Liab | 4.6M | 6.2M | 10.8M | 12.4M | 12.3M | 7.2M | |
Total Current Liabilities | 13.6M | 19.5M | 27.9M | 28.3M | 20.1M | 17.8M | |
Total Stockholder Equity | 198.9M | 105.8M | 180.1M | 109.2M | 101.0M | 127.8M | |
Other Liab | 2.2M | 4.7M | 3.0M | 3.1M | 3.5M | 3.0M | |
Net Tangible Assets | 198.9M | 105.8M | 178.4M | 106.2M | 122.2M | 129.5M | |
Net Debt | (204.9M) | (110.7M) | (177.9M) | (104.0M) | (77.2M) | (81.1M) | |
Retained Earnings | (165.9M) | (285.2M) | (340.5M) | (436.0M) | (457.5M) | (434.6M) | |
Accounts Payable | 8.5M | 9.4M | 13.6M | 14.2M | 6.1M | 9.0M | |
Cash | 207.1M | 114.6M | 181.6M | 105.8M | 78.6M | 129.7M | |
Non Current Assets Total | 4.4M | 9.7M | 10.5M | 11.0M | 16.8M | 17.6M | |
Non Currrent Assets Other | 370K | 3.3M | 3.2M | 5.7M | 12.5M | 13.1M | |
Cash And Short Term Investments | 207.1M | 114.6M | 181.6M | 105.8M | 78.6M | 129.7M | |
Common Stock Shares Outstanding | 35.2M | 40.1M | 43.2M | 43.7M | 43.6M | 41.4M | |
Liabilities And Stockholders Equity | 216.4M | 132.0M | 212.8M | 141.5M | 127.9M | 150.1M | |
Non Current Liabilities Total | 3.9M | 6.7M | 4.8M | 4.0M | 6.8M | 4.5M | |
Capital Surpluse | 225.4M | 364.7M | 391.6M | 519.2M | 597.1M | 304.2M | |
Other Current Assets | 4.8M | 7.7M | 7.5M | 5.5M | 5.0M | 4.9M | |
Other Stockholder Equity | 364.7M | 391.6M | 519.2M | 543.9M | 558.0M | 379.6M | |
Total Liab | 17.5M | 26.2M | 32.7M | 32.2M | 26.9M | 22.3M | |
Total Current Assets | 212.0M | 122.4M | 202.3M | 130.4M | 111.1M | 142.8M | |
Accumulated Other Comprehensive Income | 50K | (526K) | 1.4M | 1.3M | 449K | 349.7K | |
Other Assets | 370K | 7.9M | 206.9M | 5.7M | 1.0 | 0.95 | |
Net Invested Capital | 198.9M | 105.8M | 180.1M | 109.2M | 101.0M | 104.9M | |
Net Working Capital | 198.4M | 102.8M | 174.4M | 102.2M | 91.0M | 102.2M | |
Property Plant And Equipment Net | 4.0M | 6.4M | 5.7M | 2.3M | 1.6M | 1.6M | |
Property Plant And Equipment Gross | 4.0M | 6.4M | 5.7M | 2.3M | 1.6M | 1.6M | |
Non Current Liabilities Other | 242K | 6.7M | 4.8M | 802K | 864K | 820.8K | |
Property Plant Equipment | 4.0M | 1.8M | 5.7M | 2.3M | 2.7M | 3.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.